UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell Therapy
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
Your search for “Therapy Target” returned 457 results
Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and Safety
February 1, 2017
…of anti-cancer drugs that inhibit two or more molecular targets at once, maximizing therapeutic efficiency and safety.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
State’s Stem Cell Agency Awards $18.2 Million Grant for B Cell Cancer Clinical Trial
August 24, 2017
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.
Mutant Gene Found to Fuel Cancer-Promoting Effects of Inflammation
October 23, 2017
A study by UC San Diego biologists uncovered a new mechanism linking a human gene’s function to chronic inflammation and cancer. Through large-scale genomic analyses, they discovered that “mutant p53” amplifies the impact of inflammation, leading to increases in cancer. Thus, rather than fighting tumor growth, mutant forms of p53…
A Target for Potential Cancer Drugs May, In Fact, Worsen Disease
November 9, 2021
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
Leukemia Drug Shows Promise for Treating a Childhood Brain Cancer
September 20, 2019
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.
Two UC San Diego Scientists Receive Stem Cell Technology Grants
February 2, 2015
The governing board of the California Institute for Regenerative Medicine (CIRM) has awarded two University of California, San Diego researchers almost $3 million in combined funding to pursue new technologies intended to accelerate advances moving stem cell therapies out of the lab and into the clinic.
The Coming of Age of Stem Cell Therapy
October 30, 2014
…Age of Stem Cell Therapy Photos by Erik Jepsen/UC San Diego Publications With first clinical trials, UC San Diego pushes stem cell therapies into a new era of real-world application In 2004, the therapeutic potential of stem cells persuaded more than 7 million Californians to approve Proposition 71, which allocated…
Targeting Newly Discovered Pathway Sensitizes Tumors to Radiation and Chemotherapy
September 3, 2015
In some patients, aggressive cancers can become resistant to chemotherapy and radiation treatments. In a paper published in the journal Nature Communications, University of California, San Diego School of Medicine researchers identified a pathway that causes the resistance and a new therapeutic drug that targets this pathway.
